J&J Talc Medical Monitoring Class Action Cut to 7 States and DC as Judge Drops Nearly 30 States
A New Jersey federal judge has narrowed the talc medical monitoring class action against Johnson & Johnson to claims under the law of seven states and DC, cutting nearly 30 states ten months after he dismissed the first version. Screening claims without a cancer diagnosis now depend on which state's law applies.
Torts Desk··15 min read

The talc medical monitoring class action against Johnson & Johnson survived in part this week: Judge Michael A. Shipp of the US District Court for the District of New Jersey signed an opinion on November 19, 2026 that, as Law360 reported the next day, limits the proposed class to claims under the law of seven states and the District of Columbia and removes claims from nearly 30 others. The ruling means women who used J&J talc powders but have no cancer diagnosis may still be able to pursue a court-ordered screening program, but only where their home state's law recognizes medical monitoring without a present injury.
The case is Bynum v. Red River Talc LLC, No. 3:24-cv-07065, filed in Trenton in June 2024. It is separate from the roughly 69,000-case talc Multidistrict Litigation (MDL) before the same court, which concerns women who already have ovarian cancer. The monitoring suit is about the women who do not, and who are outside J&J's proposed $5.5 billion ovarian talc settlement.
This analysis was prepared without direct access to the November opinion, which is not yet available through a public database reachable for this report. It relies on the court's docket listings, Law360's report of the ruling, earlier coverage of the January 2026 dismissal and the April and May 2026 briefing, and the governing state law. The seven surviving jurisdictions have not been named in any accessible source, so this article does not guess at them.
What did the judge rule in the J&J talc medical monitoring class action?
Judge Shipp narrowed the case rather than ending it. According to Law360's November 20 report, the ruling trims the lawsuit brought by women who say they could develop ovarian cancer from allegedly asbestos-contaminated J&J talc, eliminating claims from nearly 30 states and leaving claims under the law of seven states plus DC.
That outcome is a notable shift from where the case stood in January. On January 29, 2026, Shipp dismissed the medical monitoring claim in the first amended complaint for failure to state a claim and struck the class allegations entirely. The plaintiffs then filed a second amended complaint pleading a multistate class. J&J moved again to dismiss the monitoring claims and strike the class allegations, arguing in an April 2, 2026 memorandum, as HarrisMartin reported, that the new pleading "does not cure" the earlier defects and noting that plaintiffs had twice before filed multistate class complaints covering millions of users. The November 19 opinion resolves that motion.
The practical reading of a seven-state-plus-DC limit is that the court sorted the claims by governing law. Medical monitoring is a creature of state law, and the states split sharply on whether a person with no diagnosed disease can recover the cost of future medical surveillance. Claims governed by the law of states that require a present physical injury were cut; claims governed by the law of states that allow some form of monitoring recovery without one were allowed to proceed at the pleading stage.
Two cautions apply. First, surviving a motion to dismiss and a motion to strike is not class certification. The plaintiffs still have to satisfy Rule 23 in a contested certification motion. Second, the procedural posture of the individual named plaintiffs matters, because the January opinion turned in part on the fact that the lead plaintiff lived in a state whose law did not support her claim.
Which states are still in the talc medical monitoring lawsuit?
The seven states have not been identified in the reporting available at publication, and the opinion itself was not accessible. What can be said is that the surviving claims arise under the law of seven states plus the District of Columbia, and that the dropped group covers nearly 30 states.
The table later in this article lists the states whose highest courts have recognized some form of medical monitoring recovery without a present physical injury. That list is background on how state law divides; it is not the court's list, and readers should check the opinion on the docket before relying on any particular state's inclusion.
How the talc medical monitoring case got here
The litigation has moved through three complaints and two major rulings in under two and a half years.
| Date | Event |
|---|---|
| June 17, 2024 | Joni Bynum, Robin Coburn and James Coburn file a putative class action in the District of New Jersey (Trenton), No. 3:24-cv-07065, seeking a J&J-funded medical monitoring program for women who used its talc products |
| 2024 to 2025 | J&J pursues its third talc bankruptcy through Red River Talc LLC; the US Bankruptcy Court for the Southern District of Texas dismisses that case on March 31, 2025 |
| 2025 | J&J moves to strike the class allegations, arguing varying state laws and individual exposure histories make class treatment impossible |
| January 29, 2026 | Judge Shipp dismisses the medical monitoring claim without prejudice and strikes the class allegations; plaintiffs get 30 days to amend |
| April 2, 2026 | J&J files a memorandum supporting dismissal of the second amended complaint and striking of its class allegations |
| May 2026 | Briefing continues on the second amended complaint, including the Coburns' motion to sever |
| November 19, 2026 | Shipp signs a memorandum opinion on the renewed motion |
| November 20, 2026 | Law360 reports the class is limited to seven states plus DC, with nearly 30 states' claims eliminated |
The plaintiffs' side has included Beasley Allen and Levin Papantonio, two of the firms most active in the talc docket. The suit was filed less than a month after talc plaintiffs' lawyers sued to block J&J's prepackaged bankruptcy plan, and J&J called the monitoring complaint "meritless" when it was filed, arguing it was an attempt to disrupt that plan. J&J maintains its talc is safe, asbestos-free and does not cause cancer.
Who is in the proposed talc medical monitoring class?
As filed in 2024, the proposed class covers US women who used J&J's talc powders, principally Johnson's Baby Powder and Shower to Shower, for genital hygiene for more than four years at any point from 1960 to the present, and who have not filed their own personal injury suit. The plaintiffs asked the court to order J&J to fund a program of "baseline assessments, diagnostic testing, and preventative measures" for ovarian and other gynecological cancers.
The January opinion described the plaintiffs as seeking certification of five classes in the first amended complaint. Part of what doomed that version was that it tried to represent both women with a present cancer diagnosis and women with no injury at all. The November reporting describes the surviving case as one brought by women who say they could develop ovarian cancer, which suggests the class now centers on undiagnosed users.
Scale is the reason the case matters to both sides. When the suit was filed, an expert quoted by Bloomberg estimated that a screening program for this population could cost J&J hundreds of millions of dollars, and possibly billions. Ovarian cancer has no validated population screening test, which is itself a point J&J has pressed: a monitoring remedy has to buy something medically useful to be recoverable.
Why did the court dismiss the talc medical monitoring claim in January 2026?
Judge Shipp dismissed the first version for two independent reasons, and both still shape the case.
The first was injury. Bynum, the lead plaintiff, had no cancer diagnosis. The court applied the law of her home state to her claim and held that both New Jersey and Washington law require a present, existing injury to support medical monitoring. The plaintiffs argued that the cost of monitoring was itself an economic injury, but the court found that the 189-page amended complaint offered only a "vague and conclusory" injury allegation and lacked factual allegations showing any economic loss. Even if economic loss had been pleaded, the court held, economic harm alone cannot sustain a medical monitoring claim in either jurisdiction, according to the defense-side Drug & Device Law Blog's account of the opinion.
The second was conflict. The class representatives were participants in the talc MDL, and the complaint sought to represent people who already had cancer alongside people who had none. Shipp found the representatives inadequate under Rule 23's adequacy of representation requirement because the interests of present and future claimants diverge, and he struck the class allegations. Subclassing did not fix the problem.
The New Jersey piece of that holding reflects a long-running tension in the state's law. In Ayers v. Township of Jackson (1987), the New Jersey Supreme Court allowed residents exposed to toxic chemicals to recover medical surveillance costs without a present physical injury. But in Sinclair v. Merck & Co. (2008), the same court held that claims covered by the New Jersey Product Liability Act require a physical injury, closing the Ayers route for product cases. A talc powder suit is a product case, which is why New Jersey law did not help the plaintiffs.
Can you sue for medical monitoring without a cancer diagnosis?
In some states, yes; in many, no. Whether a person with no diagnosed disease can recover future screening costs depends almost entirely on which state's law governs the claim, which is exactly the line the November ruling appears to draw.
There is no federal common-law route. The US Supreme Court, in Metro-North Commuter Railroad Co. v. Buckley (1997), declined to recognize a free-standing lump-sum monitoring remedy for asymptomatic workers under the Federal Employers' Liability Act, and federal courts sitting in diversity apply state law. The result is a patchwork.
| Approach | States (highest-court authority) | Basic rule |
|---|---|---|
| Monitoring recoverable without present physical injury | Pennsylvania (Redland Soccer Club v. Department of the Army, 1997); West Virginia (Bower v. Westinghouse, 1999); Utah (Hansen v. Mountain Fuel Supply, 1993); Missouri (Meyer v. Fluor Corp., 2007); California (Potter v. Firestone Tire & Rubber, 1993, as an element of damages) | Plaintiff must show significant exposure to a proven hazardous substance, increased risk, and a reasonably necessary monitoring regime |
| Recoverable with a subcellular or physiological change | Massachusetts (Donovan v. Philip Morris USA, 2009) | Requires some physiological change plus substantially increased risk |
| Recognized only as a remedy or in limited settings | Maryland (Exxon Mobil Corp. v. Albright, 2013) | Available in hazardous-exposure cases on specific proof |
| Present injury required for product claims | New Jersey (Sinclair v. Merck, 2008); Washington (as applied in Bynum, January 2026) | Monitoring tied to an existing injury |
| Rejected without present injury | New York (Caronia v. Philip Morris USA, 2013); Kentucky (Wood v. Wyeth-Ayerst, 2002); Michigan (Henry v. Dow Chemical, 2005); Mississippi (Paz v. Brush Engineered Materials, 2007); Alabama (Hinton v. Monsanto, 2001) | No independent claim absent physical injury |
Commentators also list Colorado as having rejected no-injury monitoring claims in late 2025, and Louisiana bars it by statute. The American Law Institute's work on a Restatement rule for medical monitoring has added fuel to the debate, with defense groups arguing it would expand liability. Counting the "yes" column and the closer cases, the number of plausibly receptive jurisdictions is in the high single digits, which is consistent with a surviving class of seven states plus DC.
Which states allow medical monitoring claims without a present injury?
The clearest examples are Pennsylvania, West Virginia, Utah and Missouri, whose highest courts have recognized a medical monitoring claim or remedy without a present physical injury; California allows monitoring costs as damages in toxic exposure cases, and Massachusetts allows it with proof of a subcellular change. Even in those states, the plaintiff typically must prove significant exposure to a hazardous substance, a significantly increased risk of a serious latent disease, and that a monitoring program is reasonably necessary and different from the care a person would ordinarily receive. For a talc class, the last element is contested because there is no proven ovarian cancer screening test.
The Third Circuit problem: why surviving dismissal is not certification
Even for the seven surviving jurisdictions, the class still has to be certified, and the Third Circuit, whose law binds the District of New Jersey, has been skeptical of monitoring classes.
In Barnes v. American Tobacco Co. (1998), the Third Circuit affirmed decertification of a Pennsylvania smokers' medical monitoring class, holding that the elements of a monitoring claim, including exposure, increased risk and the necessity of monitoring for each person, raised individual issues that defeated cohesiveness under Rule 23(b)(2). In Gates v. Rohm & Haas Co. (2011), it affirmed denial of certification of a medical monitoring class of residents exposed to vinyl chloride, finding that plaintiffs could not prove class-wide exposure at a level that would justify monitoring for everyone.
Those decisions map directly onto a talc class. Each woman's frequency and duration of use, the products and years involved, her baseline risk factors, and her family history all bear on whether monitoring is reasonably necessary for her. Plaintiffs will need to show that a single monitoring protocol can be justified across the class, and that commonality and predominance are satisfied for any damages component. J&J will argue, as it did in 2025, that varying state laws, causation standards and individual circumstances make class treatment impossible. Limiting the case to seven states plus DC answers part of the choice-of-law objection, but not the individualized proof problem.
There is also the general causation question. Plaintiffs' experts in the MDL withdrew specific causation opinions in bellwether cases earlier this year, which led to the July 2026 show-cause order discussed below. A monitoring class does not need to prove that talc caused any individual's cancer, but it does need to prove that exposure significantly increases the risk of ovarian cancer, which puts the same body of epidemiology back in play and invites a Daubert challenge at certification.
Does the talc medical monitoring case affect the $5.5 billion J&J talc settlement?
Not directly, but it complicates J&J's path to finality. J&J announced on July 27, 2026 that it would commit $5.5 billion to resolve the ovarian talc litigation, conditioned on express participation by lead plaintiff firms representing at least 95% of roughly 76,000 remaining claims. In October 2026, lead counsel reported that 313 firms holding about 66,500 claims, about 87.5%, had signed on. The deal covers pending ovarian claims. It does not cover mesothelioma claims or people who have not filed a claim, and it cannot bind the undiagnosed women in the monitoring class.
That gap is why the monitoring case matters. J&J has tried three times, through LTL Management twice and Red River Talc once, to use a Texas Two-Step bankruptcy to resolve future talc claims in one proceeding, and each attempt was dismissed. Without a bankruptcy channeling injunction, the only way to address future claimants as a group is through litigation like Bynum or a negotiated class settlement. A surviving seven-state monitoring class keeps that question open even if the ovarian deal closes.
The MDL itself is at a decision point. Magistrate Judge Rukhsanah L. Singh's July 22, 2026 order required every MDL plaintiff to show cause, within 120 days, why the case should not be dismissed with prejudice for failure to point to admissible specific causation expert opinion. That 120-day period ran to November 19, 2026, the same day Shipp signed the monitoring opinion, although MDL deadlines have been held in abeyance while settlement participation is reported to the court.
What happens next in Bynum v. Red River Talc?
The next steps are an answer from J&J to the surviving claims, discovery on the remaining jurisdictions, and eventually a contested motion for class certification under Rule 23. J&J may also seek reconsideration or ask the court to certify the ruling for interlocutory appeal, as it has in other talc rulings, although a partial denial of a motion to dismiss is not ordinarily appealable as of right. Plaintiffs whose states were cut could seek to amend again, refile individually where their state allows it, or preserve the issue for appeal after final judgment.
Timing points to watch are the court's handling of the Coburns' motion to sever, any scheduling order setting a certification deadline, and whether the ovarian settlement's participation condition is met or waived, which will shape how much attention both sides devote to the monitoring case in 2027.
What it means for plaintiffs' firms, defendants, insurers and funders
Plaintiffs' firms. The ruling confirms that a nationwide no-injury monitoring class is not viable in the District of New Jersey, but that a class tied to receptive jurisdictions can survive the pleadings. Firms considering monitoring classes in other mass tort dockets, such as PFAS, hair relaxer or GLP-1 litigation, should expect courts to sort claims by governing law at the outset and should plead state-specific classes with named plaintiffs from each state. The January opinion is also a warning on adequacy: named plaintiffs who are already MDL claimants, or who seek both injury and monitoring relief, invite a conflict finding.
Defendants. The decision shows that defeating a monitoring class at the pleading stage is likely to be state-by-state rather than all-or-nothing. Choice-of-law briefing should come early, and defendants with national product footprints should map their exposure in Pennsylvania, West Virginia, Utah, Missouri, California and Massachusetts in particular. The individualized-proof arguments from Barnes and Gates remain the main certification defense.
Insurers. Monitoring relief is often framed as equitable, which raises coverage questions about whether a court-ordered screening fund is "damages because of bodily injury." Carriers writing products liability towers for consumer-product companies should watch whether the surviving class seeks a fund or reimbursement.
Litigation funders. Monitoring claims have no individual payout in the usual sense, so their value lies in the size of the fund and the common benefit fee. A narrowed class reduces potential fund size but also reduces litigation risk, and it gives third-party litigation funding investors a more predictable, state-bounded asset.
FAQ
What did the judge rule in the talc medical monitoring class action?
Judge Michael A. Shipp's November 19, 2026 opinion limited the proposed class action against Johnson & Johnson to claims under the law of seven states and the District of Columbia, eliminating claims from nearly 30 states, as Law360 reported on November 20.
Can you get medical monitoring from J&J without an ovarian cancer diagnosis?
Possibly, but only if your claim is governed by the law of a state that allows medical monitoring without a present injury and the class is later certified. No monitoring program has been ordered, and New Jersey and Washington law were held in January 2026 to require a present injury.
Is the talc medical monitoring lawsuit part of the $5.5 billion J&J settlement?
No. The $5.5 billion proposal resolves pending ovarian cancer claims in MDL No. 2738 and related state cases, subject to a 95% participation condition; it does not cover women without a diagnosis who have not filed a claim.
Who is covered by the proposed talc medical monitoring class?
As originally pleaded, US women who used J&J talc powders such as Johnson's Baby Powder or Shower to Shower for genital hygiene for more than four years at any time since 1960 and who have not filed an individual lawsuit; after the November ruling, only those whose claims arise under the law of the seven surviving states or DC remain.
Why was the January 2026 complaint dismissed?
Because the lead plaintiff had no present injury, which New Jersey and Washington law require for medical monitoring, the complaint did not plead an economic loss, and the class mixed women with and without cancer in a way that created conflicts defeating adequacy of representation.
Can J&J appeal the medical monitoring ruling now?
Not as of right. A partial denial of a motion to dismiss is interlocutory, so J&J would need the district court to certify the question for appeal or wait for a later order it can challenge, such as a class certification ruling, which can be appealed only with the Third Circuit's permission under Rule 23(f).
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

J&J Talc Settlement Participation Hits 87.5%: 313 Firms In, About 5,700 Claims Short of 95%
Lead plaintiffs' counsel told the MDL 2738 court that 313 firms holding about 66,500 ovarian talc claims have signed J&J's $5.5 billion deal, 87.5% against a 95% condition. Meanwhile a Boston jury is hearing a mesothelioma case the deal never covered.
Torts Desk · 19 min

Lead Exposure Class Certification Splits: Dollar Tree Pouch Class Denied, DuPont Monitoring Class Certified
Lead exposure class certification split in three days: a New York federal judge refused to certify a class over Dollar Tree's lead-tainted WanaBana pouches, while an Indiana federal judge certified a medical monitoring class of East Chicago children against DuPont and Hammond Group but rejected their injury class.
Torts Desk · 16 min

The Talc Settlement Participation Threshold Is Now on a Two-Week Clock in MDL 2738
Every deadline in the largest MDL in the federal system is frozen while Negotiation Counsel report claimant sign-ups every two weeks, starting 15 September 2026. The talc settlement participation threshold — 95% — is a private contract term no judge will ever approve.
Torts Desk · 19 min